Abstract:Background: The global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is growing, but its subsequent health consequences have not been thoroughly examined. Methods: A phenome-wide association study was conducted to map the associations of MASLD with 948 unique clinical outcomes among 361,021 Europeans in the UK Biobank. Disease trajectory and comorbidity analyses were applied to visualize the sequential patterns of multiple comorbidities related to the occurrence of MASLD. The associations jointly verified by observational and polygenic phenome-wide analyses were further replicated by two-sample Mendelian randomization analysis using data from the FinnGen study and international consortia. Findings: The observational and polygenic phenome-wide association study revealed the associations of MASLD with 96 intrahepatic and extrahepatic diseases, including circulatory, metabolic, genitourinary, neurological, gastrointestinal, and hematologic diseases. Sequential patterns of MASLD-related extrahepatic comorbidities were primarily found in circulatory, metabolic, and inflammatory diseases. Mendelian randomization analyses supported the causal associations between MASLD and the risk of several intrahepatic disorders, metabolic diseases, cardio-cerebrovascular disease, and ascites but found no associations with neurological diseases. Conclusions: This study elucidated multisystem comorbidities and health consequences of MASLD, contributing to the development of combination interventions targeting distinct pathways for health promotion among patients with MASLD. Funding: X.L. was funded by the Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001) and the National Nature Science Foundation of China (82204019) and Y.D. was funded by the Key Project of Traditional Chinese Medicine Science and Technology Plan of Zhejiang Province (GZY-ZJ-KJ-24077) and the National Natural Science Foundation of China (82001673 and 82272860).

Reversing metabolic dysfunction-associated steatotic liver disease promotes healthy pediatric cardiovascular structures: the PROC study

Prevalence, incidence, and recovery of metabolic dysfunction-associated steatotic liver disease and associations with weight loss and lipid reduction in a Chinese community-based cohort

Cardiometabolic Phenotype Linked to Fibrosis and Mortality in Metabolic Dysfunction-Associated Steatotic Liver Disease

Multisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease

Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment

Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Breaking boundaries: Unraveling metabolic dysfunction-associated steatotic liver disease in children of India and Canada

Longitudinal evaluation of pediatric and young adult metabolic dysfunction-associated steatotic liver disease defined by MR elastography

S1910 Differential Effect of Cardiometabolic Risk Factors on Mortality in US Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)

Diet, exercise, and supplements: what is their role in the management of the metabolic dysfunction-associated steatotic liver disease in children?

Adherence to a healthy lifestyle including sleep and sedentary behaviors and risk of metabolic dysfunction-associated steatotic liver disease in Chinese adults

Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease

Gestational and Developmental Contributors of Pediatric MASLD

Prevalence of steatotic liver disease (MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents

Converging Pathways between Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Diabetes in Children

Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study

Lipidome Changes Associated with a Diet-Induced Reduction in Hepatic Fat among Adolescent Boys with Metabolic Dysfunction-Associated Steatotic Liver Disease

The prevalence and predictors of metabolic dysfunction‐associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults

Associations of the EAT-Lancet reference diet with metabolic dysfunction–associated steatotic liver disease and its severity: A multicohort study

Electrocardiographic Abnormalities in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis